دانلود اطلس بیماری های عصبی عضلانی

The first edition of this book was published in 2004, the second edition in 2014. In the ensuing years, several new developments changed our approach to patients with neuromuscular disorders. In the authors’ opinion, the most important change is that the idea of “evidence-based medicine” is now widely accepted. The Cochrane Collaboration (www.cochrane.org), the European Federation of Neurological Societies (EFNS) (www.efns.org), and the American Academy of Neurology (AAN) (www.aan.com) all provide unbiased systematic reviews of treatment paradigms with evidence-based recommendations. Increasingly, freely available sources such as the Directory of Open Access Journals (www.doaj.org) and PubMed Central (www.ncbi.nlm.nih.gov/pubmed) are used, which enable rapid and commonly unrestricted access to new medical information. These changes are reflected in updated content in the third edition of this atlas. The clinical methodology of the examination of the patient with neuromuscular disease has remained unchanged and is based on a detailed case history and a systematic neuromuscular examination. The number of antibody-associated and immune-mediated neuromuscular disorders is growing. The number of newly identified neuromuscular genetic disorders has increased dramatically and continues to evolve on a monthly basis. Open access websites, including Gene Reviews (www.ncbi.nlm.nih.gov/sites/GeneTests/review) and the Neuromuscular Home Page (neuromuscular.wustl. edu), provide up-to-date genetic and clinical information for the practitioner and information on how to attain appropriate genetic testing. As whole genome sequencing also becomes available and affordable, clinical pathways in several genetic diseases can change.